|

Midazolam Hydrochloride Clinical Trials

3 actively recruiting trials

▲ +1 trial since July 2026

Pipeline

Phase 2: 2Phase 1/2: 1

Top Sponsors

  • University Hospital of North Norway1
  • University Health Network, Toronto1
  • Joshua Rosenblat1

Indications

  • Depression3
  • Bipolar Disorder I or II1
  • Borderline Personality Disorder (BPD)1
  • Treatment-Resistant Major Depressive Disorder1
  • Treatment-resistant Bipolar Depression1

Other3 trials

Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT)
Phase 2
Ketamine for Combined Depression and Alcohol Use Disorder
Phase 1/2
i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.